ArticleWorld journal of gastroenterology2013
Metastatic type 1 gastric carcinoid: a real threat or just a myth?
Article in World journal of gastroenterology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Response and relapse rates after treatment with long-acting somatostatin analogs in multifocal or recurrent type-1 gastric carcinoids: A systematic review and meta-analysis.United European gastroenterology journal · 2020Pooled it
- Gastric neuroendocrine neoplasms type 1: A systematic review and meta-analysis.World journal of gastroenterology · 2019Pooled it
- Netazepide Inhibits Expression of Pappalysin 2 in Type 1 Gastric Neuroendocrine Tumors.Cellular and molecular gastroenterology and hepatology · 2020Trial
- Netazepide, a gastrin/cholecystokinin-2 receptor antagonist, can eradicate gastric neuroendocrine tumours in patients with autoimmune chronic atrophic gastritis.British journal of clinical pharmacology · 2017Trial
- Clinical Outcomes of Antrectomy for Patients With Multiple Type I Gastric Neuroendocrine Tumors: A Case Series.DEN open · 2027Article
- [Gastric neuroendocrine neoplasms: update on endoscopic and surgical management].Chirurgie (Heidelberg, Germany) · 2026Review
- Association Between Long-Term Proton Pump Inhibitor Use and Low-Risk Gastric Neuroendocrine Tumors.Annals of surgical oncology · 2026Article
- Controversies in NEN: An ENETS position statement on the endoscopic management of localised gastric, duodenal and rectal neuroendocrine neoplasms.Journal of neuroendocrinology · 2025Review
- Step-by-Step Approach to the Incidental Diagnosis of Type I Gastric Neuroendocrine Tumors: Practical Insights.JGH open : an open access journal of gastroenterology and hepatology · 2025Review
- A single center retrospective analysis of feasibility of diagnostic endoscopic resection for grade 1 or 2 gastric neuroendocrine tumors.Scientific reports · 2025Article
- Advances in Endoscopic Diagnosis and Treatment of Gastric Neuroendocrine Neoplasms.Digestive diseases and sciences · 2024Review
- Metastatic Type 1 low-grade gastric neuroendocrine tumor treated with peptide receptor radionuclide therapy in a young adult: a case report.Gastroenterology report · 2024Article
- Neuroendocrine mechanism of gastric acid secretion: Historical perspectives and recent developments in physiology and pharmacology.Journal of neuroendocrinology · 2023Review
- Clinical characteristics and long-term prognosis of type 1 gastric neuroendocrine tumors in a large Japanese national cohort.Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society · 2023Article
- Factors Predicting Type I Gastric Neuroendocrine Neoplasia Recurrence: A Single-Center Study.Biomedicines · 2023Article
- Prognostic value of computed tomography radiomics features in patients with gastric neuroendocrine neoplasm.Frontiers in oncology · 2023Article
- Endoscopic surveillance alone is feasible and safe in type I gastric neuroendocrine neoplasms less than 10 mm in diameter.Endocrine · 2022Article
- Usefulness of 68-Gallium PET in Type I Gastric Neuroendocrine Neoplasia: A Case Series.Journal of clinical medicine · 2022Article
- Pathogenic ATM Variant-Harbouring Well-Differentiated Aggressive Type 1 Gastric Neuroendocrine Tumour with High-grade Features (G3 NET): a New Addition to the Clinical and Pathological Spectrum of Gastric Neuroendocrine Neoplasms.Endocrine pathology · 2021Article
- Clinical Outcomes of Endoscopic Treatment for Type 1 Gastric Neuroendocrine Tumor.Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo describe disease characteristics and treatment modalities in a group of rare patients with metastatic gastric carcinoid type 1 (GCA1).
methodsInformation on clinical, biochemical, radiological, histopathological findings, the extent of the disease, as well as the use of different therapeutic modalities and the long-term outcome were recorded. Patients' data were assessed at presentation, and thereafter at 6 to 12 monthly intervals both clinically and biochemically, but also endoscopically and histopathologically. Patients were evaluated for the presence of specific symptoms; the presence of autoimmune disorders and the presence of other gastrointestinal malignancies in other family members were also recorded. The evaluation of response to treatment was defined using established WHO criteria.
resultsWe studied twenty consecutive patients with a mean age of 55.1 years. The mean follow-up period was 83 mo. Twelve patients had regional lymph node metastases and 8 patients had liver metastases. The primary tumor mean diameter was 20.13 ± 10.83 mm (mean ± SD). The mean Ki-67 index was 6.8% ± 11.2%. All but one patient underwent endoscopic or surgical excision of the tumor. The disease was stable in all but 3 patients who had progressive liver disease. All patients remained alive during the follow-up period.
conclusionMetastatic GCA1 carries a good overall prognosis, being related to a tumor size of ≥ 1 cm, an elevated Ki-67 index and high serum gastrin levels.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.